CRISPR deletion of the C9ORF72 promoter in ALS/FTD patient motor neurons abolishes production of dipeptide repeat proteins and rescues neurodegeneration

GGG GCC (G4C2) repeat expansion in the first intron of C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) [6, 11]. Brain tissues from affected individuals show characteristic nuclear RNA foci containing the expanded repeat RNAs, as well as neuronal inclusions containing dipeptide repeat (DPR) proteins [poly(GA), poly(GP), poly(GR), poly(PR), and poly(PA)] resulting from the translation of both sense and antisense repeat RNAs in all reading frames [4, 9, 14]. Although reduced C9ORF72 protein function may contribute to disease [10], the more likely drivers of disease are mechanisms related to a gain of toxic function [7]. Currently, intense efforts are being made to identify disease mechanisms amenable for the development of therapeutic strategies. One promising avenue would be to prevent the production of the expanded repeat RNAs, such as by antisense oligonucleotides [5]. Here, we tested another potential therapeutic approach: CRISPR/Cas9-based targeting of the promoter region. In ALS and FTD patients, transcription initiated at exon1a of C9ORF72 generates RNA species containing G4C2 repeat expansions that are in turn translated into three DPR proteins, poly(GA), poly(GP), and poly(GR). Thus, we first used reporter constructs to identify the promoter sequence 5′ to exon-1a that is responsible for transcription initiation of expanded repeat RNA. We cloned the 435 nucleotides (nt) upstream of the predicted transcription initiation site, as well as several truncated fragments of the 435-nt sequence, into a luciferase reporter vector (Fig. 1a) and expressed all the constructs in HEK293 cells. Deletion of the first 301 nt did not reduce the relative expression of the reporter gene. However, deleting the remaining 134 nt abolished luciferase expression (Fig. 1a), indicating that the core promoter elements are located in this region. To further characterize this sequence, we also tested a construct lacking the first 394 nt and one lacking the remaining 41 nt. Each of these deletions reduced the relative luciferase expression, indicating that both constructs lacked a portion of sequence required for reporter gene expression (Fig. 1a). These experiments indicate that the last 134 nt sequence contains the minimal promoter necessary to drive expression of G4C2 repeat-containing C9ORF72 transcripts. To investigate how this deletion affects the production of RNAs containing G4C2 repeat expansions in C9ORF72 human neurons, we used CRISPR-Cas9 technology to generate a similar deletion 5′ to exon-1a of C9ORF72 in an induced pluripotent stem cell (iPSC) line containing ~ 1000 copies of the G4C2 repeats [2] (Figs. 1b, c; S1). We selected two iPSC lines containing the promoter deletion and differentiated them and the parental iPSC line into ChAT-positive motor neurons (see Suppl. Information). As expected, the promoter deletion eliminated the expression of C9ORF72Variant 3 (V3), whose transcription starts on exon-1a (Fig. 1b, d). In contrast, the RNA level of C9ORF72-V2, whose translation starts on exon 1b, or the expression of C9ORF72-antisense RNA, was not significantly affected Gopinath Krishnan and Yu Zhang contributed equally to this work.

GGG GCC (G 4 C 2 ) repeat expansion in the first intron of C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) [6,11]. Brain tissues from affected individuals show characteristic nuclear RNA foci containing the expanded repeat RNAs, as well as neuronal inclusions containing dipeptide repeat (DPR) proteins [poly(GA), poly(GP), poly(GR), poly(PR), and poly(PA)] resulting from the translation of both sense and antisense repeat RNAs in all reading frames [4,9,14]. Although reduced C9ORF72 protein function may contribute to disease [10], the more likely drivers of disease are mechanisms related to a gain of toxic function [7]. Currently, intense efforts are being made to identify disease mechanisms amenable for the development of therapeutic strategies. One promising avenue would be to prevent the production of the expanded repeat RNAs, such as by antisense oligonucleotides [5]. Here, we tested another potential therapeutic approach: CRISPR/Cas9-based targeting of the promoter region.
In ALS and FTD patients, transcription initiated at exon-1a of C9ORF72 generates RNA species containing G 4 C 2 repeat expansions that are in turn translated into three DPR proteins, poly(GA), poly(GP), and poly(GR). Thus, we first used reporter constructs to identify the promoter sequence 5′ to exon-1a that is responsible for transcription initiation of expanded repeat RNA. We cloned the 435 nucleotides (nt) upstream of the predicted transcription initiation site, as well as several truncated fragments of the 435-nt sequence, into a luciferase reporter vector (Fig. 1a) and expressed all the constructs in HEK293 cells. Deletion of the first 301 nt did not reduce the relative expression of the reporter gene. However, deleting the remaining 134 nt abolished luciferase expression (Fig. 1a), indicating that the core promoter elements are located in this region. To further characterize this sequence, we also tested a construct lacking the first 394 nt and one lacking the remaining 41 nt. Each of these deletions reduced the relative luciferase expression, indicating that both constructs lacked a portion of sequence required for reporter gene expression (Fig. 1a). These experiments indicate that the last 134 nt sequence contains the minimal promoter necessary to drive expression of G 4 C 2 repeat-containing C9ORF72 transcripts.
To investigate how this deletion affects the production of RNAs containing G 4 C 2 repeat expansions in C9ORF72 human neurons, we used CRISPR-Cas9 technology to generate a similar deletion 5′ to exon-1a of C9ORF72 in an induced pluripotent stem cell (iPSC) line containing ~ 1000 copies of the G 4 C 2 repeats [2] (Figs. 1b, c; S1). We selected two iPSC lines containing the promoter deletion and differentiated them and the parental iPSC line into ChAT-positive motor neurons (see Suppl. Information). As expected, the promoter deletion eliminated the expression of C9ORF72-Variant 3 (V3), whose transcription starts on exon-1a (Fig. 1b, d). In contrast, the RNA level of C9ORF72-V2, whose translation starts on exon 1b, or the expression of C9ORF72-antisense RNA, was not significantly affected Gopinath Krishnan and Yu Zhang contributed equally to this work.
( Fig. 1e-f), consistent with the fact that these transcripts have their own promoters [6]. In iPSCs and motor neurons harboring the promoter deletion, we detected a reduction in the levels of full-length C9ORF72 protein (Figs. 1g; S2), likely due to loss of C9ORF72-V3 expression.
Since RNAs containing the G 4 C 2 repeat expansion lead to the production of DPR proteins, we next measured DPR protein levels in parental and promoter deletion motor neuron cultures using Meso Scale Discovery immunoassays. We found that expression of poly(GA), poly(GP), and poly(GR) was almost completely abolished in the motor neuron cultures harboring the promoter deletion (Fig. 2a-c). We then examined the functional consequence of reducing DPR levels in these neurons, using axonal degeneration as our Four-week-old motor neurons from parental and promoter deletion lines were analyzed for expression of C9ORF72-V3, C9ORF72-V2, and C9ORF72antisense RNAs (n = 3 independent differentiations). g C9ORF72 protein levels in 4-week-old parental and promoter deletion motor neurons (n = 3 independent differentiations). Values are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (a, e-g, one-way ANOVA; d, Welch's t test). ns not significant scoring metric as we reported recently [12]. Deletion of the promoter region prevented the increase in axonal degeneration of parental motor neurons upon withdrawal of neurotrophic factors for 2 weeks (Figs. 2d, e; S3), a phenotype we previously described in neurons differentiated from two pairs of isogenic C9ORF72 iPSC lines [12]. The promoter deletion also prevented upregulation of the expression of the heat shock protein HSPA1B mRNA (Fig. 2f), a phenotype detected in ALS/FTD patient brain tissues and C9ORF72 iPSC-derived motor neurons [3,8].
Our results indicate that deletion of the 134 nt minimal promoter 5′ to exon-1a in C9ORF72 prevents both Fig. 2 Effects of C9ORF72 promoter deletion in iPSC-derived neurons. a-c Poly(GA), poly(GP), and poly(GR) levels in 1.5-month-old parental neurons, neurons without repeats, and promoter deletion motor neurons (n = 3 independent differentiations) were measured with Meso Scale Discovery immunoassays. The poly(GA) assay was done in a blinded manner at Biogen. d Representative immunofluorescence images of the axonal degeneration assay done with the marker βΙΙΙ-tubulin (TUJ1 + ), which revealed swollen varicosities and axonal fragments. Arrowheads indicate fragmented axons. e Axonal degeneration assessed by measuring the ratio of fragmented axons over the total TUJ1 + area 2 weeks after withdrawal of neurotrophic factors. Six to eight randomly selected fields were analyzed for each condition and each neuronal culture. Each independent data point represents one field, (n = 3 independent differentiations). f Relative expression of HSPA1B in 10-week-old motor neuron cultures (n = 3 independent differentiations). Values are mean ± SEM. *p < 0.05, ***p < 0.001 (one-way ANOVA, Dunnett's multiple comparisons test) the production of sense RNAs containing expanded G 4 C 2 repeats and the activation of downstream neurodegeneration pathways. These findings also suggest that sense repeat RNA and its translation products are responsible for the observed neurodegenerative phenotypes, at least in this experimental system. The promoter deletion also partially decreased C9ORF72 protein levels. However, in the absence of DPR proteins, loss of C9ORF72 does not cause neurodegeneration in mice or iPSC-derived motor neurons [1,10]. Improved versions of the CRISPR interference are now being tested in vivo to silence gene transcription without cutting genomic DNA [13]. Thus, our proof-of-concept study suggests that CRISPR/Cas9-based targeting of the promoter region to eliminate sense repeat RNA and its toxic translation products may be a potentially useful therapeutic approach for C9ORF72-ALS/FTD, especially before significant accumulation of DPR proteins.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.